OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
301602$17.6655

Shantou Institute of Ultrasonic Instrument Co Ltd

Advanced Medical Equipment & TechnologyVerified

The company maintains a strong liquidity position, with a current ratio of 11.62, indicating a significant buffer of current assets over current liabilities. Its liquidity_fpt score suggests a medium liquidity risk, which is consistent with the company's low long-term debt and high cash flow generation. The operating cash flow of 135,253,400 CNY supports its operational needs and provides flexibility for future investments. In terms of profitability, the company's return on equity (ROE) of 10.94% and return on assets (ROA) of 10.01% are strong indicators of efficient capital utilization and asset management. These metrics are well above the industry median for Advanced Medical Equipment & Technology, suggesting a competitive edge in generating returns from equity and assets. The company's revenue is primarily concentrated in its domestic market, with no disclosed international revenue segments. This geographic concentration may expose the company to regulatory and economic risks specific to China. The business is not segmented into multiple product lines or geographic regions, which limits the visibility into diversification strategies. Looking at the growth trajectory, the company's revenue has shown consistent growth, supported by its strong operating cash flow and high net income margin. The outlook for the current fiscal year indicates a positive direction, with a projected increase in revenue and earnings. The company's capital expenditure of -15,203,330 CNY suggests a reduction in investment, which may be a strategic move to preserve cash or a sign of slower expansion. The risk assessment highlights a low dilution potential, with no significant dilution sources identified in the recent filings. The company's low debt-to-equity ratio and strong equity base reduce the likelihood of near-term dilution. However, the risk assessment notes that net cash is negative after subtracting total debt, which could be a concern if the company faces unexpected liquidity needs. Recent events, including the latest financial filing, indicate a stable financial position with no major disruptions. The company has not disclosed any significant legal or regulatory issues in the recent period. The absence of recent earnings call transcripts or major announcements suggests a lack of volatility in the company's operations.

30-day price · 301602(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyShantou Institute of Ultrasonic Instrument Co Ltd
Ticker301602.SZ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Shantou Institute of Ultrasonic Instrument Co Ltd designs, develops, and produces ultrasonic medical equipment, primarily used in diagnostic imaging and therapeutic applications.

Classification. The company is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

The company maintains a strong liquidity position, with a current ratio of 11.62, indicating a significant buffer of current assets over current liabilities. Its liquidity_fpt score suggests a medium liquidity risk, which is consistent with the company's low long-term debt and high cash flow generation. The operating cash flow of 135,253,400 CNY supports its operational needs and provides flexibility for future investments. In terms of profitability, the company's return on equity (ROE) of 10.94% and return on assets (ROA) of 10.01% are strong indicators of efficient capital utilization and asset management. These metrics are well above the industry median for Advanced Medical Equipment & Technology, suggesting a competitive edge in generating returns from equity and assets. The company's revenue is primarily concentrated in its domestic market, with no disclosed international revenue segments. This geographic concentration may expose the company to regulatory and economic risks specific to China. The business is not segmented into multiple product lines or geographic regions, which limits the visibility into diversification strategies. Looking at the growth trajectory, the company's revenue has shown consistent growth, supported by its strong operating cash flow and high net income margin. The outlook for the current fiscal year indicates a positive direction, with a projected increase in revenue and earnings. The company's capital expenditure of -15,203,330 CNY suggests a reduction in investment, which may be a strategic move to preserve cash or a sign of slower expansion. The risk assessment highlights a low dilution potential, with no significant dilution sources identified in the recent filings. The company's low debt-to-equity ratio and strong equity base reduce the likelihood of near-term dilution. However, the risk assessment notes that net cash is negative after subtracting total debt, which could be a concern if the company faces unexpected liquidity needs. Recent events, including the latest financial filing, indicate a stable financial position with no major disruptions. The company has not disclosed any significant legal or regulatory issues in the recent period. The absence of recent earnings call transcripts or major announcements suggests a lack of volatility in the company's operations.
Key takeaways
  • The company has a strong liquidity position with a current ratio of 11.62, indicating a significant buffer of current assets over current liabilities.
  • The company's ROE of 10.94% and ROA of 10.01% are strong indicators of efficient capital utilization and asset management.
  • The company's revenue is primarily concentrated in its domestic market, which may expose it to regulatory and economic risks specific to China.
  • The company's capital expenditure is negative, suggesting a reduction in investment, which may be a strategic move to preserve cash or a sign of slower expansion.
  • The company has a low dilution potential, with no significant dilution sources identified in the recent filings.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$405.5M
Gross profit$288.0M
Operating income$170.6M
Net income$148.9M
R&D
SG&A
D&A
SBC
Operating cash flow$135.3M
CapEx-$15.2M
Free cash flow$101.4M
Total assets$1.49B
Total liabilities$126.9M
Total equity$1.36B
Cash & equivalents
Long-term debt$1.7M
Valuation
Market price$17.66
Market cap$7.56B
Enterprise value$7.57B
P/E50.8
Reported non-GAAP P/E
EV/Revenue18.7
EV/Op income44.4
EV/OCF55.9
P/B5.6
P/Tangible book5.6
Tangible book$1.36B
Net cash-$1.7M
Current ratio11.6
Debt/Equity0.0
ROA10.0%
ROE10.9%
Cash conversion91.0%
CapEx/Revenue-3.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 160 companies
Metric301602Activity
Op margin42.1%-24.0% medp25 -212.9% · p75 6.1%top quartile
Net margin36.7%-20.7% medp25 -188.5% · p75 4.8%top quartile
Gross margin71.0%49.8% medp25 36.6% · p75 67.4%top quartile
CapEx / revenue-3.8%-4.7% medp25 -11.2% · p75 -1.8%above median
Debt / equity0.0%3.6% medp25 0.0% · p75 22.2%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-22 02:10 UTCJob: 847c3021